Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 15:10:516.
doi: 10.3389/fonc.2020.00516. eCollection 2020.

Response to Preoperative Therapy in Localized Pancreatic Cancer

Giampaolo Perri  1 , Laura R Prakash  1 , Matthew H G Katz  1
Affiliations
Review

Response to Preoperative Therapy in Localized Pancreatic Cancer

Giampaolo Perri et al. Front Oncol. .

Abstract

Evaluation of response to preoperative therapy for patients with pancreatic adenocarcinoma has been historically difficult. Therefore, preoperative regimens have generally been selected on the basis of baseline data such as radiographic stage and serum CA 19-9 level and then typically administered for a pre-specified duration as long as 6 months or more. The decision to proceed with resection following preoperative therapy likewise has rested upon the absence of disease progression rather than evidence for tumor response. This article reviews the basis for the evaluation of therapeutic response after preoperative therapy for pancreatic cancer in the existing scientific literature, and providing updates and new perspectives.

Keywords: pancreatic cancer; pathologic response; preoperative therapy; radiographic response; tumor response.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Current evaluation of response to preoperative therapy for pancreatic cancer and potential future bio-markers.
See this image and copyright information in PMC

References

    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res. (2014) 74:2913–21. 10.1158/0008-5472.CAN-14-0155 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, (2019). CA Cancer J Clin. (2019) 69:7–34. 10.3322/caac.21551 - DOI - PubMed
    1. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. (2018) 379:2395–406. 10.1056/NEJMoa1809775 - DOI - PubMed
    1. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. . Pancreatic adenocarcinoma, version 2.2017, nCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. (2017) 15:1028–61. 10.6004/jnccn.2017.0131 - DOI - PubMed
    1. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. . Potentially curable pancreatic cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. (2016) 34:2541–56. 10.1200/JCO.2016.67.5553 - DOI - PubMed

LinkOut - more resources